Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.…
Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target
Viridian Therapeutics (NASDAQ: VRDN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 252 employees.
The shares were at 29.96 USD on 20 November 2026, up 8.9% over 52 weeks. Its 52-week range is 13.18 USD to 34.29 USD: the price is 12.6% below the high and 127.3% above the low.
Its market capitalisation is 3.40B USD.
Viridian Therapeutics reports return on equity of -47.4% and revenue down 63.5% year over year.
It holds more cash than debt, a net cash position of 709.71M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 16 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 42.76 USD is 42.7% above the current price. The next earnings report is expected on 25 February 2027.